These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1124 related items for PubMed ID: 14687597

  • 1. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ, Johnston SR, Howell A.
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [Abstract] [Full Text] [Related]

  • 2. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR.
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [Abstract] [Full Text] [Related]

  • 3. Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.
    Baumann CK, Castiglione-Gertsch M.
    Drugs; 2007 Dec; 67(16):2335-53. PubMed ID: 17983255
    [Abstract] [Full Text] [Related]

  • 4. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A, Howell SJ, Clarke R, Anderson E.
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [Abstract] [Full Text] [Related]

  • 5. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK, Castiglione-Gertsch M.
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [Abstract] [Full Text] [Related]

  • 6. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF.
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [Abstract] [Full Text] [Related]

  • 7. Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    Robertson JF, Come SE, Jones SE, Beex L, Kaufmann M, Makris A, Nortier JW, Possinger K, Rutqvist LE.
    Eur J Cancer; 2005 Feb; 41(3):346-56. PubMed ID: 15691633
    [Abstract] [Full Text] [Related]

  • 8. Preliminary experience with pure antiestrogens.
    Howell A.
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4369s-4375s; discussion 4411s-4412s. PubMed ID: 11916227
    [Abstract] [Full Text] [Related]

  • 9. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Künzer H, Lichtner RB, Nishino Y, Parczyk K, Sauer G, Gieschen H, Ulbrich HF, Schneider MR.
    J Natl Cancer Inst; 2004 Feb 04; 96(3):210-8. PubMed ID: 14759988
    [Abstract] [Full Text] [Related]

  • 10. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).
    Lewis-Wambi JS, Jordan VC.
    Breast Dis; 2004 Feb 04; 24():93-105. PubMed ID: 16917142
    [Abstract] [Full Text] [Related]

  • 11. Future use of selective estrogen receptor modulators and aromatase inhibitors.
    Howell A.
    Clin Cancer Res; 2001 Dec 04; 7(12 Suppl):4402s-4410s; discussion 4411s-4412s. PubMed ID: 11916232
    [Abstract] [Full Text] [Related]

  • 12. Selective estrogen receptor modulators in clinical practice: a safety overview.
    Ellis AJ, Hendrick VM, Williams R, Komm BS.
    Expert Opin Drug Saf; 2015 Jun 04; 14(6):921-34. PubMed ID: 25936229
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K, Curran MP, Plosker GL.
    Drugs; 2004 Jun 04; 64(6):633-48. PubMed ID: 15018596
    [Abstract] [Full Text] [Related]

  • 15. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
    Jordan VC, Brodie AM.
    Steroids; 2007 Jan 04; 72(1):7-25. PubMed ID: 17169390
    [Abstract] [Full Text] [Related]

  • 16. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer.
    Parker LM.
    Clin Ther; 2002 Jan 04; 24 Suppl C():C43-57. PubMed ID: 12117075
    [Abstract] [Full Text] [Related]

  • 17. Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer.
    Robertson JF.
    Clin Ther; 2002 Jan 04; 24 Suppl A():A17-30. PubMed ID: 11911506
    [Abstract] [Full Text] [Related]

  • 18. Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.
    Jones SE.
    Semin Oncol; 2003 Oct 04; 30(5 Suppl 16):14-20. PubMed ID: 14613022
    [Abstract] [Full Text] [Related]

  • 19. Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body.
    Gadducci A, Cosio S, Genazzani AR.
    Curr Opin Investig Drugs; 2004 Oct 04; 5(10):1031-44. PubMed ID: 15535424
    [Abstract] [Full Text] [Related]

  • 20. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
    Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L, Muñoz C, Vega E, Calderón MJ, Sancho B, Cortes-Funes H.
    Breast; 2014 Jun 04; 23(3):201-8. PubMed ID: 24589524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.